• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Fidelity Select Biotechnology

Fidelity Select Biotechnology

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

  2. 2013: Readers Share Greatest Hits, Biggest Misses

    Biotech rules and bonds disappoint for many Morningstar.com readers.

  3. Oil plunge means Big Mac savings and big-money carnage

    Oil plunge means Big Mac savings and big-money carnage

  4. How Fidelity Funds Stacked Up in 2013

    Fidelity's growth-leaning equity funds and more conservative bond funds made for a strong year for the fund firm, says Morningstar analyst Katie Reichart.

  5. What Investors Were Researching in September

    International opportunities, income, and M&A activity were on investors' minds in September.

  6. Vanishing Stars Need Not Cause Alarm

    Funds that held up better than their peers in 2008 soon may not compare as favorably, as five-year returns move forward.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.